Survodutide
An investigational GLP-1 and glucagon dual receptor agonist studied for obesity and metabolic liver disease (MASH/NASH). Encouraging early data, but not approved.
Quick take
- What it is: an investigational peptide that activates two receptors: GLP-1 and glucagon.
- What it is being studied for: obesity and metabolic liver disease (MASH, formerly NASH).
- What we actually know: mid-stage human trials report weight loss and improvements in liver disease markers; pivotal results are pending.
- Status: investigational — in clinical trials, not approved by the FDA.
What it is
Survodutide is an investigational GLP-1 and glucagon dual receptor agonist — a peptide designed to activate both receptors with a single molecule. It is being studied for obesity and for metabolic liver disease (MASH, formerly called NASH). It is not approved by the FDA for any use.1
How it works
GLP-1 is an incretin hormone that stimulates insulin, slows gastric emptying and reduces appetite. Glucagon acts on the liver and energy metabolism and can reduce liver fat and increase energy expenditure. Survodutide combines both signals, with the theory that the glucagon component is particularly relevant for liver fat and inflammation in addition to weight.1,2 Whether this delivers durable benefit at acceptable safety is still being established.
What the evidence shows
Animal studies
Preclinical work on GLP-1/glucagon dual agonism suggested potential for combined effects on body weight and liver fat, supporting progression to human trials.2
Human studies
Mid-stage human trials of survodutide have reported meaningful weight reductions and, in liver-disease studies, improvements in markers of MASH.3 These results are encouraging but remain preliminary, pending larger and longer pivotal trials and a regulatory decision. Until those complete, conclusions about durable benefit and safety are provisional.
Dosages reported in the literature
Informational only. Survodutide is an investigational drug. The figures below describe doses used in studies; they are not a recommendation or a prescription. This compound is not approved and should only be received within a regulated clinical trial.
| Setting | Route | Reported range |
|---|---|---|
| Clinical trials (titrated) | Subcutaneous, weekly | Escalating doses studied across a range; set by trial protocol |
Because survodutide is investigational, no dose here should be read as established as safe or effective for general use.
Safety & side effects
In trials, the most commonly reported side effects have been gastrointestinal — nausea, vomiting and diarrhea — typical of this drug class, often dose-related. Effects related to glucagon activity are also under study.3 Because long-term, real-world safety data are limited, the full risk profile is not yet known.
A practical concern in the unregulated market is product quality. “Research” survodutide sold outside of clinical trials does not carry the quality, purity or dose assurances of an approved medicine.
Legal & regulatory status
Survodutide is not approved by the FDA for any use. It is investigational and being evaluated in clinical trials for obesity and metabolic liver disease. Rules differ by country and change over time.1
References
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. [PMID 38330987, doi:10.1016/S2213-8587(23)00356-X]
- Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec;66:101633. [PMID 36356832, doi:10.1016/j.molmet.2022.101633]
- Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024 Jul 25;391(4):311-319. [PMID 38847460, doi:10.1056/NEJMoa2401755]